QueerMed
- Peptide Therapy
- Erectile Dysfunction (ED) Treatment
- Hormone Replacement Therapy (HRT)
- Testosterone Replacement Therapy (TRT)
Decatur, GA
Decatur has an Emory-adjacent DeKalb market with a progressive integrative medicine leaning, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across Oakhurst, downtown Decatur, and Avondale Estates range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the Emory Decatur and Emory University Hospital network. The scene here skews toward integrative and functional medicine clinics with academic-adjacent prescribers. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable Decatur clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Regulatory context
Most research peptides used in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin hold FDA approvals for specific indications. The FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list during 2023 and 2024, restricting which peptides 503A compounding pharmacies may source. Section 503A applies to traditional patient-specific compounding; Section 503B covers FDA-registered outsourcing facilities held to cGMP.
The Georgia Board of Pharmacy inspects compounding facilities under USP 795 and USP 797 standards. Non-resident pharmacies shipping peptides into Georgia must hold a non-resident pharmacy permit. The Board has taken action against pharmacies for sterile compounding deficiencies and for sourcing ingredients inconsistent with FDA rules.